Quality improvement of tuberculosis screening in foreign-born patients.

In the United States, a disproportionate percentage of tuberculosis (TB) cases occur in foreign-born persons. We implemented a performance improvement project to improve rates of screening for latent tuberculosis infection in a medical clinic. A questionnaire was developed to identify patients for tuberculosis screening, which was performed as a Tuberculin Skin Test (TST). Patients with positive skin tests underwent further testing. One hundred and sixty-five patients were screened, with 58 TSTs ordered and 36 placed. Twenty-seven patients returned to have the TST read with 12 positive. Eleven of these patients had chest X-rays, 2 revealing findings suggestive of active TB. This project identifies the importance of a standardized TB screening process for high-risk patients and identifies barriers to such a process.

On-site Night Float by Attending Physicians: A Model to Improve Resident Education and Patient Care.

BACKGROUND: In 2003, the Accreditation Council for Graduate Medical Education instituted common duty hour limits, and in 2008 the Institute of Medicine recommended additional limits on continuous duty hours. Using a night-float system is an accepted approach for adhering to duty hour mandates. OBJECTIVE: To determine the effect of an on-site night-float attending physician on resident education and patient care. METHODS: Night-float residents and daytime ward residents were surveyed at the end of their rotation about the impact of an on-site night-float attending physician on education and quality of patient care. Responses were provided on a 5-point Likert scale ranging from 1, strongly agree, to 5, strongly disagree. RESULTS: Overall, 92 of the 140 distributed surveys were completed (66% response rate). Night-float residents found the night-float attending physician to be helpful with cross-cover issues (mean  =  2.00), initial history and physical examination (mean  =  1.56), choosing appropriate diagnostic tests (mean  =  1.79), developing a treatment plan (mean  =  1.74), and improving overall patient care (mean  =  1.91). Daytime ward residents were very satisfied with the quality of the admission workups (mean  =  1.78), tests and diagnostic procedures (mean  =  1.76), and initial treatment plan (mean  =  1.62) provided by the night-float service. CONCLUSION: A night-float system that includes on-site attending physician supervision can provide a valuable opportunity for resident education and may help improve the quality of patient care.

HIV infection and travel: pretravel recommendations and health-related risks.

In the current era of globalization and ease of air travel combined with the increased survival attained since the advent of potent antiretroviral therapy, HIV-infected individuals are traveling to remote and resource-limited areas of the world. Travel-related health risks in a patient with HIV depend on the patient's immune status, destination, travel itinerary, and type of travel. HIV-infected patients with a CD4+ count of 200 cells/mm3 or lower, particularly those who are treatment-naive and newly diagnosed, are at increased risk of complications when traveling to resource-poor settings. These increased risks include those of acquiring gastrointestinal, respiratory, and endemic tropical infectious diseases. Individuals with a CD4+ count higher than 200 cells/mm3 (whether receiving antiretroviral treatment or not) are considered to have limited immune deficiency for the purpose of travel-related recommendations; in general, they may safely receive most recommended and required vaccines. Pretravel consultation before departure is crucial to address strategies to protect against vaccine-preventable diseases (routine, recommended, and required vaccinations); vector-borne diseases, particularly malaria; gastrointestinal infections; and sexually transmitted diseases. HIV-infected travelers who are ill, particularly those with fever, should undergo an immediate medical evaluation to rule out the possibility of a life-threatening infectious disease such as malaria.

What have we learned from the novel influenza A (H1N1) pandemic in 2009 for strengthening pandemic influenza preparedness?

We need to apply lessons learned from previous influenza pandemics to continuously update preparedness and response plans. It has become evident that strengthening networks of international referral laboratories coupled with scaling-up efforts to expand epidemiological surveillance networks is critical for responding and mitigating the impact of influenza pandemics. The current swine-related influenza A (H1N1) pandemic has also shown that international collaboration remains a critical component to effectively respond to influenza pandemics in the current globalized world.

Five-year experience with type 1 and type 2 reactions in Hansen disease at a US travel clinic.

Very few data have been reported on the epidemiology and clinical features of leprosy reactions in non-endemic settings. We performed a retrospective descriptive analysis to define the frequency and features of Type 1 and Type 2 leprosy reactions in a cohort of patients followed at a US travel and tropical medicine clinic in a 5-year period. We identified that leprosy reactions presented in 10/14 (71.4%) patients with leprosy seen at our clinic. We identified that leprosy reactions occur frequently among patients living in non-endemic areas and may occur before the initiation of multi-drug therapy (MDT), during MDT, or even years after completion of therapy and may produce significant neurologic sequelae. This group of patients needs long-term clinical monitoring even after completion of MDT because of the need to continue either anti-inflammatory therapy, presence of severe neurologic sequelae after reactions, or the potential occurrence of late leprosy reactions.

Pneumocystis jiroveci pneumonia in patients with AIDS in the inner city: a persistent and deadly opportunistic infection.

Highly active antiretroviral therapy (HAART) has decreased the morbidity and mortality of opportunistic infections including Pneumocystis jiroveci pneumonia (PCP) among HIV-infected individuals. We performed a hospital-based retrospective cohort study among a population of medically underserved inner city persons living in Atlanta, Georgia, diagnosed with confirmed PCP to compare the epidemiology and outcomes of PCP during 2 defined periods: 1990 to 1995, or pre-HAART period, and 1996 to 2001, or HAART period. A total of 488 patients were available for analysis. The overall mortality rate was 47% during the pre-HAART era compared with 37% during the HAART era (P = 0.02). However, among those patients that required medical intensive care unit admission and mechanical ventilation, the mortality rate was particularly high, with over 80% of patients dying as a result of their episode of PCP during both periods. PCP was the initial presentation of HIV infection in 39.3% in the pre-HAART period with a mortality rate of 52%, in contrast with 37% in the HAART period, with a mortality rate of 45%, respectively (P = NS). Only 30.7% in the pre-HAART period and 31.1% of patients in the HAART period were receiving PCP prophylaxis. The overall risk of death, when we combined both groups in the analysis, was higher for those patients who did not take PCP prophylaxis, those who smoked tobacco, and those who were admitted to the medical intensive care unit and required mechanical ventilatory support. Our findings suggest that despite the availability of HAART, PCP continues to cause a significant burden of disease among inner-city HIV-infected populations.

Chagas disease: an impediment in achieving the Millennium Development Goals in Latin American

It presents informations about chagas disease and how this disease is impending the goals of Millennium Development Goals in Latin American. Document in PDF format, required Acrobat Reader.

Chagas disease: an impediment in achieving the Millennium Development Goals in Latin America.

BACKGROUND: Achieving sustainable economic and social growth through advances in health is crucial in Latin America within the framework of the United Nations Millennium Development Goals. DISCUSSION: Health-related Millennium Development Goals need to incorporate a multidimensional approach addressing the specific epidemiologic profile for each region of the globe. In this regard, addressing the cycle of destitution and suffering associated with infection with Trypanosoma cruzi, the causal agent of Chagas disease of American trypanosomiasis, will play a key role to enable the most impoverished populations in Latin America the opportunity to achieve their full potential. Most cases of Chagas disease occur among forgotten populations because these diseases persist exclusively in the poorest and the most marginalized communities in Latin America. SUMMARY: Addressing the cycle of destitution and suffering associated with T. cruzi infection will contribute to improve the health of the most impoverished populations in Latin America and will ultimately grant them with the opportunity to achieve their full economic potential.

El virus del Oeste del Nilo: una realidad en México / West Nile virus: a reality in Mexico

El virus del Oeste del Nilo (VON) es un virus ARN perteneciente a la familia Flaviviridae del género Flavivirus que causa infección en aves, equinos y humanos. La infección por VON es transmitida por el mosquito Culex sp. El ciclo de vida del virus incluye a los mosquitos como vectores y a las aves como huéspedes naturales. El virus mantiene un ciclo de transmisión mosquito–ave-mosquito. Los seres humanos son huéspedes accidentales. Se han reportado epidemias en Rumania, Nueva York e Israel. Mediante el programa de vigilancia epidemiológica en nuestro país, se han reportado 90 muestras positivas en 1,223 casos estudiados en aves hasta el 15 de Septiembre del 2005. La enfermedad por el VON se presenta con fiebre, malestar general, anorexia, nausea, vómito, cefalea, mialgia, erupción cutánea y linfadenopatía. La principal entidad clínica descrita es la encefalitis y la parálisis flácida. A mayor edad, es mayor el riesgo de enfermedad neurológica y muerte. Los métodos diagnósticos incluyen determinación de anticuerpos IgM e IgG en suero y/o liquido cerebroespinal. No existe tratamiento antiviral para la infección por VON. Algunas terapias que se han utilizado incluyen interferón α2b e inmunoglobulina específica contra VON. La prevención juega un papel crucial.

West Nile virus (WNV) is a RNA virus of the Flaviridae, genus flavivirus family. It is a neuropathogenic virus causing disease in birds, horses and humans. WNVis transmitted by the vector mosquito Culex sp. The virus life 's cycle includes mosquitoes as vectors and birds as natural hosts. Humans are accidental hosts. Since the introduction of the Epidemiological Surveillance Program at the Ministry ofHealth. we have documented 90 positive test results among birds out of 1,223 cases studied in Mexico as of September IS. 2005. The incubation period in humans after a mosquito bite ranges from 3 to 14 days. Disease is characterized by early onset fever, general malaise, decreased appetite, nausea, vomiting, headaches, myalgias, enlarged lymph nodes andrash. Neurological manifestations include encephalitis andflaccid paralysis, which are present in less than 1% of subjects infected with WNV. Older patients display more adverse outcomes including death. The diagnosis is made by the determination of specific IgM and JgG antibodies in serum and/or cerebrospinal fluid. There is no antiviral treatment to date against WNV but interferon ?2b, and WNVspec4ic-immunoglobulin have been used Prevention is therefore the key to control the infection.

Rapid HIV testing: a review of the literature and implications for the clinician.

HIV counseling and testing services are critical for individuals to access HIV prevention and treatment. Unfortunately, the standard HIV testing algorithm is complex and includes the use of a sensitive enzyme immunoassay (EIA), followed by a Western blot if the EIA is positive. This process can take 1 week or longer. Therefore, innovative approaches that incorporate simpler diagnostic algorithms are needed to reach the large number of individuals who are not aware that they are HIV-infected. Currently available rapid HIV tests have demonstrated sensitivities and specificities comparable to those of standard HIV testing without the requirements of sophisticated laboratory resources or highly trained personnel. These rapid HIV tests are increasingly being used in various clinical scenarios to decrease the number of missed opportunities for detection of HIV-infection. Their use is particularly applicable in specific clinical and nonclinical settings; public health settings; labor and delivery wards; in the management of occupational exposures; and in resource-constrained settings. The overarching goals of achieving wide implementation of rapid HIV tests are to increase the number of individuals who are aware of their serostatus, to improve entry of persons with HIV into prevention and care services, and to prevent further HIV transmission.

Microbiology of acute sinusitis in Mexican patients.

Acute bacterial sinusitis is a common disorder affecting children and adults. We performed a study to assess the bacteriology of acute sinusitis in a community hospital in Mexico City. Patients with an acute exacerbation of persistent sinusitis or acute sinusitis were enrolled. Aspiration of sinus secretions was performed and aspirates were sent for culture. All patients received antibiotic treatment for the infection based on microbiologic sensitivity reports. Follow-up consultation included endoscopy and a computed tomography scan of paranasal sinuses to assess response to treatment. A total of 110 patients were enrolled for evaluation. Forty nine percent of patients were women; median age was 31 years. A total of 136 cultures were recovered for analysis. Twenty seven percent of cultures were negative. Isolated organisms were Haemophilus influenzae (26%), Moraxella catarrhalis (15%), Streptococcus pneumoniae (14%), methicillin-sensitive Staphylococcus aureus (7%), enterobacteriaceae (6%), Pseudomonas aeruginosa (2%) and miscellaneous (3%). Twenty eight percent of H. influenzae strains were resistant to ampicillin. Penicillin-sensitive S. pneumoniae (PSSP) and penicillin-intermediate-resistant S. pneumoniae (PISP) accounted for 21% and 79% of the S. pneumoniae strains, respectively. H. influenzae was the most common isolated organism. About 55% of those isolates were found in patients <18 years old and only 25% were resistant to ampicillin. Sinus endoscopy continues to be a useful diagnostic tool in addition to imaging studies in sinus infection and should be pursued by the clinician whenever feasible.

[West Nile virus: a reality in Mexico]. / El virus del Oeste del Nilo: una realidad en México.

West Nile virus (WNV) is a RNA virus of the Flaviridae, genus flavivirus family. It is a neuropathogenic virus causing disease in birds, horses and humans. WNVis transmitted by the vector mosquito Culex sp. The virus life 's cycle includes mosquitoes as vectors and birds as natural hosts. Humans are accidental hosts. Since the introduction of the Epidemiological Surveillance Program at the Ministry ofHealth. we have documented 90 positive test results among birds out of 1,223 cases studied in Mexico as of September IS. 2005. The incubation period in humans after a mosquito bite ranges from 3 to 14 days. Disease is characterized by early onset fever, general malaise, decreased appetite, nausea, vomiting, headaches, myalgias, enlarged lymph nodes andrash. Neurological manifestations include encephalitis andflaccid paralysis, which are present in less than 1% of subjects infected with WNV. Older patients display more adverse outcomes including death. The diagnosis is made by the determination of specific IgM and JgG antibodies in serum and/or cerebrospinal fluid. There is no antiviral treatment to date against WNV but interferon ?2b, and WNVspec4ic-immunoglobulin have been used Prevention is therefore the key to control the infection.

[Confronting bioterrorism: Epidemiologic, clinical, and preventive aspects of smallpox]. / Enfrentando el bioterrorismo: aspectos epidemiológicos, clínicos y preventivos de la viruela.

The worldwide eradication of smallpox, a major achievement in public health, is currently threatened by the risk of bioterrorism. The debate on the destruction of the Variola virus in the two reference laboratories of the World Health Organization has dramatically switched to the preservation of the remaining virus after the September 2001 terrorist events in the U.S. along with the intentional release of Bacillus anthracis in the U.S. The risk of intentional release of Variola virus constitutes a minimal, yet possible risk. A smallpox epidemic could have a devastating impact due to its elevated morbidity and mortality that would inflict in non-immune human population, in addition to the ensuing panic and social unrest. Therefore, the development of national preparedness and response plans along with the availability of smallpox vaccine to be used in the post-exposure phase represent a fundamental part of the preventive efforts to cope with bioterrorism. Reestablishing a preventive vaccination program was recently recommended by the Advisory Committee on Immunization Practices (ACIP). However, the vaccine currently available has historically been associated with serious adverse reactions, even death. Thus, this recommendation has not been universally accepted. To counter an epidemic of smallpox, medical personnel in the frontline need to be prepared with updated smallpox information to identify, diagnose, isolate, and treat cases if a bioterrorist attack should occur. Herein we present an indepth review for health care personnel with relevant epidemiologic, clinical, and preventive information on smallpox.

Enfrentando el bioterrorismo: aspectos epidemiológicos, clínicos y preventivos de la viruela / Confronting bioterrorism: epidemiologic, clinical, and preventive aspects of smallpox

Uno de los grandes logros de la salud pública mundial, la erradicación de la viruela, puede verse mermado por el posible riesgo de bioterrorismo. El debate acerca de la destrucción de los restos del virus en los dos laboratorios de referencia de la Organización Mundial de la Salud ha cambiado diametralmente debido a los eventos terroristas y a la dispersión intencional de Bacillus anthracis ocurridos en poblaciones civiles en Estados Unidos de América en el año 2001. La liberación del virus Variola con fines terroristas constituye un riesgo mínimo no cuantificable, pero desafortunadamente real. El impacto podría ser devastador debido a la elevada morbimortalidad de la enfermedad aunada al pánico y a la desestabilización social que podría ocasionar. Es por ello que el establecimiento de un plan de respuesta, sumado a disponibilidad de vacuna para ser utilizada pos-exposición, es importante dentro de los planes de contingencia contra el bioterrorismo. El reiniciar un programa limitado de vacunación contra la viruela, como parte de dicho plan, ha sido recientemente recomendado por el Comité Asesor de Vacunación, del Centro para el Control de las Enfermedades, pero la vacuna disponible puede causar complicaciones graves e incluso la muerte, por lo que dicha recomendación no ha sido universalmente aceptada. No obstante, el personal médico y de salud pública requiere de información actualizada sobre la viruela y su prevención, ya que ellos son la primera línea de defensa en caso de un posible brote a consecuencia de un ataque bioterrorista. El presente artículo presenta una revisión dirigida a proporcionar al personal de salud un enfoque clínico, epidemiológico y preventivo sobre la viruela